99mTc-EC-Cox-2

home

pipeline

EC Mechanism

quarterly reports





Click here for animation

< ^99mTc-EC-Cox-2 >

The company plans to prepare and file an IND application with the FDA during the fourth quarter 2005 to conduct clinical imaging studies with 99mTc-EC-Cox-2. The study protocol will focus on colorectal cancer. It is expected that the Cox-2 inhibitor to be used in the study will be Celebrex. The company expects to commence the clinical study by the second quarter 2006.

© copyright 2001-2007|Cell>Point L.L.C | all rights reserved | maintained by Link2City.com

Terry Colip

Home | About Us | Management Team | Scientific Advisory Board | Corporate fact Sheet
EC Mechanism of Action | Video | R & D | Agents Pipeline | News | Articles | Patents | Corp Financials | Contact Us